Followers | 43 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, October 21, 2022 1:30:15 PM
NexImmune Highlights FDA Clearance Of IND For NEXI-003 For The Treatment Of HPV-Related Cancers
Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company's first solid tumor product candidate for the treatment of HPV-related cancers
Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22
Clinical updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 4Q22
Company is prioritizing resources to support Company's lead product candidates, NEXI-001 and NEXI-003
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”
my posts are always theory and not financial advice
Recent NEXI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 11:58:48 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/11/2024 09:17:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:28:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 09:10:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:01:30 PM
- Approbation des résultats financiers du groupe au 31 mars 2024, poursuite de la croissance et de l’augmentation de la marge de BAIIA, lancement d’un programme de rachat d’actions de 500 millions € • Business Wire • 05/09/2024 04:39:00 PM
- Konzernabschluss zum 31. März 2024 verabschiedet, kontinuierliches Wachstum und Ausweitung der EBITDA-Marge, Aktienrückkaufprogramm in Höhe von 500 Millionen Euro gestartet • Business Wire • 05/09/2024 04:39:00 PM
- Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, € 500 Million Share Buy-Back Program Launched • Business Wire • 05/09/2024 06:00:00 AM
- Konzernergebnis zum 31. Dezember 2023 genehmigt, starke Margenausweitung und Liquiditätsüberschuss von 601 Millionen Euro, Aktienrückkaufprogramm von 500 Millionen Euro • Business Wire • 03/07/2024 06:20:00 PM
- Approbation des résultats financiers du groupe au 31 décembre 2023 ; forte expansion de la marge et génération d'excédents de trésorerie à hauteur de 601 millions d’euros ; programme de rachat d’actions de 500 millions d’euros • Business Wire • 03/07/2024 05:33:00 PM
- Approvati i risultati finanziari di Gruppo al 31 dicembre 2023, Forte espansione dell’EBITDA margin ed excess cash generation a € 601 milioni, € 500 milioni per acquisto di azioni proprie • Business Wire • 03/07/2024 06:31:00 AM
- Group Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back Program • Business Wire • 03/07/2024 06:30:00 AM
- NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 02/06/2024 09:42:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/06/2024 09:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 10:10:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/05/2024 09:34:15 PM
- NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 02/02/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 06:25:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:17:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:43:51 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/18/2024 09:43:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:01:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 06:39:59 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 11/22/2023 10:40:35 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM